BAX and neoplasm: In the multivariate survival analysis (Table 3), BAX mRNA expression remained a statistically significant predictor of longer DFS in NPC, independent of patients’ gender, age, tumor histology, tumor extent, and regional lymph node status, as patients with BAX mRNA-positive tumors were more prone to relapse (HR = 0.35, 95% CI = 0.15–0.86, P = 0.022).